Immunotherapy shines in tumor treatment. In 2021, more than 100 monoclonal antibody drugs have been approved. In addition to monospecific antibodies, the development of multispecific antibodies is also in full swing. AtRead More…
Human immunodeficiency virus 1 (HIV-1) is a retrovirus, and most HIV-1 infections occur on the mucosal surface of the human reproductive tract. After HIV-1 enters the nucleus of the host cell, itRead More…
G protein-coupled receptor (GPCR) is a very important receptor protein on the cell surface. In the human genome, GPCR-encoding genes account for more than 2% and contain more than 800 members, makingRead More…
In the past, components of adaptive immunity were thought to play non-overlapping roles in antimicrobial host defense, with antibodies targeting pathogens in the extracellular environment and T cells responsible for eliminating intracellularRead More…
In a new study, researchers from Emory University revealed that cancer-causing mutations result in widespread distortions in protein-protein interaction networks in cells. The findings were recently published online in the journal Cell.Read More…
Cancer has become the second largest health threat in the world, with about 10 million people dying of cancer in 2020. For decades, cytotoxic-based chemotherapy has been the main treatment for allRead More…
Even through relying on the immune system of patients, cancer immunotherapy is still far from fully utilizing the entire body’s natural defense system. In fact, most of these treatments only utilize theRead More…
Multiple myeloma is a largely incurable cancer of plasma cells with an extremely poor prognosis. However, in a recent study published in Science Translational Medicine entitled “Selective targeting of multiple myeloma cellsRead More…
Vascular dysfunction contributes to the pro-oncogenic tumor microenvironment and impedes the delivery of therapeutic drugs, so normalizing tumor blood vessels may become a potential path. Scientists have developed a new type ofRead More…
CD38 protein, which was discovered in 1980, is a type II transmembrane glycoprotein with a size of 46 kDa. The ligand of CD38 is CD31, also known as PECAM-1, which is aRead More…